Physician profile
Scott E Pollard
NPI 1851366314
$1,046.10
in general payments reported to CMS, 2019-2025
13 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62.68 · 2020: $69.59 · 2021: $87.62 · 2022: $285 · 2023: $281 · 2024: $139 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $541.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $541.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $239.98 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $230.26 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $138.63 | 2022-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $115.32 | 2019-2022 | |
| Alkermes, INC. | $86.74 | 2023-2024 | Lybalvi, Aristada, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.53 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.06 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $36.17 | 2023 | Austedo Xr, Austedo |
| Supernus Pharmaceuticals, INC. | $32.77 | 2022-2023 | Qelbree |
| Corium, LLC | $29.21 | 2022-2023 | Azstarys |
| Harmony Biosciences LLC | $22.63 | 2023 | Wakix |
| Vanda Pharmaceuticals INC. | $21.74 | 2024 | Fanapt |
| Eisai INC. | $16.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Pollard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.